Parkinson’s Disease and Latent (Hidden) Viruses: CBCD Reports an Important Discovery on the Cause of the Disease

January 15, 2021

Parkinson’s Disease and latent (hidden viruses) study: The cause of most Parkinson’s disease cases is unknown. However, it is well documented that mitochondrial dysfunction and misfolded α synuclein aggregation are important cellular abnormalities associated with the disease.

In this paper, we use the microcompetition model to show how latent viruses, which infect the central and peripheral nervous systems, can cause the observed mitochondrial dysfunction and excess α synuclein aggregation, and eventually, Parkinson’s disease. View study here published in the Journal of NeuroVirology.

The discovery was made possible by using the microcompetition model.  The model uncovered new relationships between seemingly unrelated observations reported in the scientific literature.  The discovery describes the molecular steps that lead from a latent infection to the clinical symptoms of Parkinson’s disease.  Many common viruses can cause the disease. They include the Epstein-Barr virus (EBV), Cytomegalovirus (CMV), Herpes Simplex Virus 1 (HSV-1), and Varicella Zoster Virus (VZV).

The model shows that an increase in the concentration of these viruses, or copy number, during the latent phase, increases the risk of developing Parkinson’s disease.  What can increase this viral copy number? A damaged immune system.  Events that decrease the efficiency of the immune system include aging, certain medications, surgery, chemotherapy, radiation, stress, and more.

The microcompetition model was used to discover the effects of latent viruses on other diseases too. It was used to show how latent viruses can cause breast cancer (2), and other cancers (3).  The model was created by Hanan Polansky, and was introduced in his book: “Microcompetition with Foreign DNA and the Origin of Chronic Disease.”

For jobs in medicine click here.


References

(1)  Polansky H, Lori G. How microcompetition with latent viruses can cause α synuclein aggregation, mitochondrial dysfunction, and eventually Parkinson’s disease. J Neurovirol. 2021 Jan 6. doi: 10.1007/s13365-020-00929-x

(2)  Polansky H, Schwab H. How latent viruses cause breast cancer: An explanation based on the microcompetition model. Bosn J Basic Med Sci. 2019 Aug 20;19(3):221-226. doi: 10.17305/bjbms.2018.3950.

(3)  Polansky H, Schwab H. Copy number of latent viruses, oncogenicity, and the microcompetition model. Oncotarget. 2018 Aug 3;9(60):31568-31569. doi: 10.18632/oncotarget.25804. eCollection 2018 Aug 3.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”